Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $9.67 Analyst target: $20.56 Upside: 112.62%
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
See the full interactive analysis & chart →Informational only — not investment advice.